What to Do if Bilirubin is High
First, determine whether the elevated bilirubin is conjugated (direct) or unconjugated (indirect), as this fundamentally directs all subsequent evaluation and management 1, 2.
Initial Diagnostic Approach
The critical first step is fractionating the bilirubin to distinguish between conjugated and unconjugated hyperbilirubinemia 3. This single test determines whether you're dealing with a hemolytic/metabolic disorder versus hepatocellular injury or biliary obstruction.
For Unconjugated Hyperbilirubinemia
If the majority of elevated bilirubin is unconjugated and the patient is otherwise well, Gilbert's syndrome is virtually always the cause in the absence of hemolysis 2. These patients require:
- Complete blood count to exclude hemolysis
- Review of medications (including vitamins, herbs, over-the-counter drugs) 1
- Assessment for signs of hemolytic disorders
If Gilbert's syndrome is confirmed, provide complete reassurance—no further workup or treatment is needed 2. This is a benign inherited disorder of bilirubin conjugation with reduced glucuronyltransferase activity.
For hemolysis, consider:
- G6PD deficiency (particularly in males of Mediterranean, Middle Eastern, or African descent—think of this especially if bilirubin rises late) 4
- Other hemolytic anemias based on CBC findings
For Conjugated Hyperbilirubinemia
When conjugated bilirubin is elevated, you must assess for biliary obstruction and hepatocellular disease 1, 2. The initial laboratory panel should include:
- Alkaline phosphatase (ALP)
- γ-glutamyltransferase (GGT) to confirm hepatic origin of elevated ALP 2
- Alanine transaminase (ALT) and aspartate transaminase (AST)
- Albumin and prothrombin time/INR (assess synthetic function)
- Complete blood count 3
If ALP is elevated along with conjugated bilirubin, obtain abdominal ultrasonography immediately to exclude biliary obstruction 1, 2. Ultrasonography is the least invasive and least expensive initial imaging method 3.
Pattern Recognition for Conjugated Hyperbilirubinemia:
- Cholestatic pattern (ALP/GGT elevated more than aminotransferases): Think biliary obstruction, primary biliary cholangitis, drug-induced cholestasis
- Hepatocellular pattern (aminotransferases elevated more than ALP): Think viral hepatitis, alcoholic hepatitis, drug-induced liver injury, autoimmune hepatitis
Clinical Context Matters
Do not follow an algorithmic approach blindly if clinical clues point to a specific diagnosis—pursue that diagnosis directly 1. Key historical elements include:
- Alcohol consumption patterns
- All medications, supplements, and herbal products
- Risk factors for viral hepatitis
- Family history of liver disease
- Symptoms: pruritus, abdominal pain, weight loss, fever
- Signs: hepatomegaly, splenomegaly, ascites, spider angiomas
When to Expedite Evaluation
Persistent hyperbilirubinemia (>6 months), markedly elevated levels, or any signs of chronic/decompensated liver disease warrant expeditious and complete diagnostic evaluation 1. This includes:
- Viral hepatitis serologies (hepatitis A, B, C)
- Autoimmune markers if indicated
- Ceruloplasmin for Wilson disease in younger patients
- Iron studies for hemochromatosis
- Consider liver biopsy for chronic elevations without clear etiology
Common Pitfalls to Avoid
Don't assume low albumin means liver disease alone—it drops in sepsis, nephrotic syndrome, malabsorption, and protein-losing enteropathy 2
Don't ignore conjugated hyperbilirubinemia—it always requires investigation for obstruction or parenchymal disease 1
Don't repeat bilirubin levels serially without acting—if bilirubin is elevated in the setting of cholecystitis or symptomatic cholelithiasis, proceed directly to imaging or intervention rather than trending levels 5
Don't overlook medication-induced hyperbilirubinemia—obtain a complete medication history including all over-the-counter products 1
Special Population: Neonates
In neonates and infants with conjugated bilirubin >25 μmol/L, refer urgently to pediatrics to exclude biliary atresia and other serious causes 2. This is a time-sensitive diagnosis where delayed treatment worsens outcomes.
For unconjugated neonatal hyperbilirubinemia, the 2022 AAP guidelines raised thresholds for phototherapy, reducing unnecessary interventions 6, 7, 8, 9.